EP3600275A1 - Composition de sirop pharmaceutique stabilisée comprenant du sulfate de terbutaline et du chlorhydrate d'ambroxol - Google Patents
Composition de sirop pharmaceutique stabilisée comprenant du sulfate de terbutaline et du chlorhydrate d'ambroxolInfo
- Publication number
- EP3600275A1 EP3600275A1 EP17721224.8A EP17721224A EP3600275A1 EP 3600275 A1 EP3600275 A1 EP 3600275A1 EP 17721224 A EP17721224 A EP 17721224A EP 3600275 A1 EP3600275 A1 EP 3600275A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- ambroxol
- terbutaline
- syrup
- pharmaceutical
- syrup composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000006188 syrup Substances 0.000 title claims abstract description 50
- 235000020357 syrup Nutrition 0.000 title claims abstract description 50
- QNVKOSLOVOTXKF-UHFFFAOYSA-N 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;hydron;chloride Chemical compound Cl.NC1=C(Br)C=C(Br)C=C1CNC1CCC(O)CC1 QNVKOSLOVOTXKF-UHFFFAOYSA-N 0.000 title claims abstract description 37
- 229960000985 ambroxol hydrochloride Drugs 0.000 title claims abstract description 36
- KFVSLSTULZVNPG-UHFFFAOYSA-N terbutaline sulfate Chemical compound [O-]S([O-])(=O)=O.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1 KFVSLSTULZVNPG-UHFFFAOYSA-N 0.000 title claims abstract description 34
- 239000000203 mixture Substances 0.000 title claims description 51
- 208000006673 asthma Diseases 0.000 claims abstract description 20
- 206010006482 Bronchospasm Diseases 0.000 claims abstract description 8
- 208000009079 Bronchial Spasm Diseases 0.000 claims abstract description 7
- 208000014181 Bronchial disease Diseases 0.000 claims abstract description 7
- 208000019693 Lung disease Diseases 0.000 claims abstract description 5
- 230000028327 secretion Effects 0.000 claims abstract description 5
- 239000002562 thickening agent Substances 0.000 claims abstract description 5
- 238000011418 maintenance treatment Methods 0.000 claims abstract description 4
- 229960005174 ambroxol Drugs 0.000 claims description 30
- JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 claims description 30
- 238000009472 formulation Methods 0.000 claims description 27
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 25
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 25
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 25
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims description 24
- 229960000195 terbutaline Drugs 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 10
- 239000013543 active substance Substances 0.000 claims description 8
- AJOQVCHLLULVGK-UHFFFAOYSA-N 4-(6,8-dibromo-2,4-dihydro-1h-quinazolin-3-yl)cyclohexan-1-ol Chemical compound C1CC(O)CCC1N1CC2=CC(Br)=CC(Br)=C2NC1 AJOQVCHLLULVGK-UHFFFAOYSA-N 0.000 claims description 6
- 238000003860 storage Methods 0.000 claims description 6
- 229920002678 cellulose Polymers 0.000 claims description 5
- 239000001913 cellulose Substances 0.000 claims description 5
- 235000010980 cellulose Nutrition 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 12
- 238000011282 treatment Methods 0.000 abstract description 12
- 230000015556 catabolic process Effects 0.000 abstract description 10
- 208000030603 inherited susceptibility to asthma Diseases 0.000 abstract description 10
- 238000006731 degradation reaction Methods 0.000 abstract description 9
- 239000004480 active ingredient Substances 0.000 abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 239000012535 impurity Substances 0.000 description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- 239000003814 drug Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 9
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 8
- 229960002303 citric acid monohydrate Drugs 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000008367 deionised water Substances 0.000 description 7
- 229910021641 deionized water Inorganic materials 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- XUKUURHRXDUEBC-SXOMAYOGSA-N (3s,5r)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-SXOMAYOGSA-N 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 206010011224 Cough Diseases 0.000 description 5
- 239000000048 adrenergic agonist Substances 0.000 description 5
- 239000003172 expectorant agent Substances 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- 241000220223 Fragaria Species 0.000 description 4
- 235000016623 Fragaria vesca Nutrition 0.000 description 4
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 229940126157 adrenergic receptor agonist Drugs 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 206010006451 bronchitis Diseases 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 239000012669 liquid formulation Substances 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 4
- 239000004299 sodium benzoate Substances 0.000 description 4
- 235000010234 sodium benzoate Nutrition 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 239000008371 vanilla flavor Substances 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000007857 degradation product Substances 0.000 description 3
- 229940126534 drug product Drugs 0.000 description 3
- 229940088679 drug related substance Drugs 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229940066491 mucolytics Drugs 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 150000005846 sugar alcohols Polymers 0.000 description 3
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 description 2
- 206010006458 Bronchitis chronic Diseases 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 206010013911 Dysgeusia Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000022120 Jeavons syndrome Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 2
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- OJGDCBLYJGHCIH-UHFFFAOYSA-N bromhexine Chemical class C1CCCCC1N(C)CC1=CC(Br)=CC(Br)=C1N OJGDCBLYJGHCIH-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000007451 chronic bronchitis Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 230000000420 mucociliary effect Effects 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 238000010979 pH adjustment Methods 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 229910021653 sulphate ion Inorganic materials 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 239000006068 taste-masking agent Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GHUMSGGCKVMYGH-UHFFFAOYSA-N (2-amino-3,5-dibromophenyl)methanol Chemical compound NC1=C(Br)C=C(Br)C=C1CO GHUMSGGCKVMYGH-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010049153 Allergic sinusitis Diseases 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010015543 Eustachian tube dysfunction Diseases 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
- 238000010268 HPLC based assay Methods 0.000 description 1
- 208000016621 Hearing disease Diseases 0.000 description 1
- BFSMWENDZZIWPW-UHFFFAOYSA-N Isopropamide iodide Chemical compound [I-].C=1C=CC=CC=1C(C(N)=O)(CC[N+](C)(C(C)C)C(C)C)C1=CC=CC=C1 BFSMWENDZZIWPW-UHFFFAOYSA-N 0.000 description 1
- 240000004836 Justicia adhatoda Species 0.000 description 1
- YIICVSCAKJMMDJ-UHFFFAOYSA-N L-vasicine Natural products C1=CC=C2N=C3C(O)CCN3CC2=C1 YIICVSCAKJMMDJ-UHFFFAOYSA-N 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- YIICVSCAKJMMDJ-SNVBAGLBSA-N Peganine Chemical compound C1=CC=C2N=C3[C@H](O)CCN3CC2=C1 YIICVSCAKJMMDJ-SNVBAGLBSA-N 0.000 description 1
- YIICVSCAKJMMDJ-JTQLQIEISA-N Peganine Natural products C1=CC=C2N=C3[C@@H](O)CCN3CC2=C1 YIICVSCAKJMMDJ-JTQLQIEISA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 description 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 229960003870 bromhexine Drugs 0.000 description 1
- UCDKONUHZNTQPY-UHFFFAOYSA-N bromhexine hydrochloride Chemical compound Cl.C1CCCCC1N(C)CC1=CC(Br)=CC(Br)=C1N UCDKONUHZNTQPY-UHFFFAOYSA-N 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 230000007883 bronchodilation Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- HFNCOTSLOKKPHU-UHFFFAOYSA-N cyclohexanol;hydrochloride Chemical compound Cl.OC1CCCCC1 HFNCOTSLOKKPHU-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960002146 guaifenesin Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- -1 hydrobromate Chemical class 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 229940041682 inhalant solution Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960001543 isopropamide iodide Drugs 0.000 description 1
- PTVWPYVOOKLBCG-ZDUSSCGKSA-N levodropropizine Chemical compound C1CN(C[C@H](O)CO)CCN1C1=CC=CC=C1 PTVWPYVOOKLBCG-ZDUSSCGKSA-N 0.000 description 1
- 229960002265 levodropropizine Drugs 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000000510 mucolytic effect Effects 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- YCIMNLLNPGFGHC-UHFFFAOYSA-N o-dihydroxy-benzene Natural products OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000002445 parasympatholytic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- YXJYBPXSEKMEEJ-UHFFFAOYSA-N phosphoric acid;sulfuric acid Chemical compound OP(O)(O)=O.OS(O)(=O)=O YXJYBPXSEKMEEJ-UHFFFAOYSA-N 0.000 description 1
- 239000006069 physical mixture Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 1
- 229960001755 resorcinol Drugs 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 1
- 229960002586 roflumilast Drugs 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000003033 spasmogenic effect Effects 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229940127230 sympathomimetic drug Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Definitions
- the present invention relates to combined use of terbutaline or a pharmacologically acceptable salt thereof, which is a B2-adrenergic receptor agonist; and ambroxol or a pharmacologically acceptable salt thereof which is a mucolytic agent; and to pharmaceutical compositions of syrup form comprising this combination and to the fields of use thereof.
- the pharmaceutical syrup formulation of the present invention is stabilized against degradation of the active ingredients.
- Terbutaline is a B 2 -adrenergic receptor agonist with a molecular formula of C 12 H 19 N0 3 , chemical name of which is (RS-5-[2-(tert)-butylamino)-l-hydroxyethyl] benzene- 1 , 3 -diol. It is marketed under the trade name Bricanyl® (AstraZeneca).
- Bricanyl® AstraZeneca
- Terbutaline is a synthetic sympathomimetic agent which basically acts as a B 2 -agonist. It belongs to Biopharmaceutics classification system (BCS) class II drugs which is widely used in treatment of bronchial asthma. The plasma half-life of about 3- 4 hours, also the drug undergoes first pass metabolism and has poor bioavailability (Gobade NG et al., 2012).
- Terbutaline is an adrenergic agonist which provides relaxation of bronchial smooth muscles basically by stimulating B 2 -receptors; inhibition of endogenous spasmogenic secretion; inhibition of edema caused by endogenous mediators; increase in mucociliary clearance; and relaxation of uterus muscle. It has the following pharmacological effects: l i) In the lung: bronchodilation; increase in mucociliary clearance; suppression of edema and anti-allergic effects.
- skeletal muscle stimulates Na7K + transport and also causes depression of subtetanic contractions in slow-contracting muscle.
- Terbutaline was firstly described in the patent numbered BE 704932.
- This patent comprises processes for preparation of terbutaline; pharmaceutical compositions comprising terbutaline; and use of terbutaline in the treatment of lung diseases such as bronchial asthma, chronic bronchitis, acute bronchospasm, asthma, bronchospasm prophylaxis and chronic obstructive pulmonary disease.
- lung diseases such as bronchial asthma, chronic bronchitis, acute bronchospasm, asthma, bronchospasm prophylaxis and chronic obstructive pulmonary disease.
- terbutaline or a pharmacologically acceptable salt is used, preferably terbutaline sulphate is used.
- Ambroxol is a metabolite of bromhexine (Bisolvon ®), which is itself derived from vasicine, a plant extract from the Malabar nut plant.
- Bisolvon ® bromhexine
- ambroxol hydrochloride is used.
- other acid addition salt including hydrobromate, oxalate, nitrate, sulphonate, fumarate, maleate, sulfate phosphate, and the like or freebase can also be used.
- Chemical name of ambroxol hydrochloride is trans-4-[2-amino-3,5-dibromobenzyl] amino] cyclohexanol hydrochloride.
- the structural formula is represented below (Formula II):
- Ambroxol is an active substance with a local analgesic, mucolytic and antiinflammatory effect which is used to treat sore throats and respiratory diseases accompanied by viscous mucus formation, e.g. in acute aggravations of chronic bronchitis, asthmatic bronchitis and bronchial asthma. It is currently available under the brand names Mucosolvan® (Boehringer Ingelheim).
- Ambroxol is usually present in medicaments in the form of ambroxol hydrochloride. It belongs to Biopharmaceutics classification system (BCS) class II drugs used as an expectorant, mucolytic agent to treat acute and chronic diseases. It has short plasma half-life 4 hours require frequent daily dosing (2-3 times) (Md. Mizanur Rahman Moghal et al., 2012). It is commercially available, in the form of suckable lozenges, capsules, as an inhalation solution, syrup and linctus.
- BCS Biopharmaceutics classification system
- ambroxol is used for the treatment of acute sore throat owing to its analgesic effect, and it is generally prepared into a syrup formulation so that it acts fast and has a long lasting analgesic effect of at least 3 hours (deMey C. et al., Arzneistoffforschung., 2008, 58(1 1 ): 557558).
- groups administered with a syrup formulation containing 20 mg of ambroxol showed a significant reduction in pain, as well as fast (30 minutes after the administration) and a long lasting analgesic effect (at least 3 hours).
- asthma reactions are characterized by symptoms such as streaming, itching and reddening of the eyes (allergic conjunctivitis); nasal flow, itching and blockage (allergic rhinitis); allergic sinusitis in sinuses; itching, reddening and eruption of the skin (urticaria); nuisance, distension, vomiting and diarrhea in gastrointestinal system; feeling of blockage, ache, hearing disorders associated with dysfunction of Eustachian tube in ears; snooze, cough, bronchoconstriction, shortness of breath, sniffling, asthma attacks and constriction of respiratory tract associated with edema (angioedema) in respiratory tract. Allergies can also trigger asthma attacks. Asthma is a reversible airway constriction characterized in short breath and sniffle occurring as attacks. Asthma is one of the few chronic diseases most frequently seen in children and adults.
- US2003/0171391 discloses a pharmaceutical composition containing ambroxol or an acceptable salt thereof for the treatment of diseases which are based on powerful activation of voltage-dependent sodium channels, particularly for the treatment of chronic pain.
- US/391 discloses an aqueous solution comprising an acid addition salt of ambroxol, wherein the ambroxol content is ranging from 0.1 % to 7% (w/v), and the total content of polyalcohols selected from polyols and/or polyalkyleneglycols is at least 20% (w/v), the total content of alcohols is lower than 1 % (w/v).
- CN105287367 A discloses a pharmaceutical preparation, and in particular relates to an oral liquid preparation of ambroxol hydrochloride as well as a preparation method and application of the oral liquid preparation.
- EP 1417961 A1 relates to novel pharmaceutical compositions comprising as pharmacologically active compounds a combination of an expectorant-effective amount of bromhexine or ambroxol or a pharmacologically acceptable salt thereof and a parasympatholytic (anticholinergic)-effective amount of isopropamide iodide.
- WO 2013/154347 relates a liquid formulation for oral administration comprising ambroxol, levodropropizine and a buffering agent, and a method for preparing such formulation are provided.
- WO 2013/081565 relates to combined use of roflumilast, which is a selective phosphodiesterase-4 (PDE-4) enzyme inhibitor, and terbutaline, which is a ⁇ 2 adrenergic receptor agonist; and to drug compositions comprising this pharmaceutical combination that can be used in the allergic and inflammatory diseases of skin or upper and lower respiratory tracts.
- PDE-4 selective phosphodiesterase-4
- Impurities in drug substance may cause adverse side effects in a patient, and hence the purity of an active ingredient is one of the most important factors in providing safe and effective pharmaceutical formulation.
- Such impurities not only include compounds which can be completely removed during the manufacturing process of the active ingredients, but also the breakdown products which can be produced by various environmental factors, e.g., temperature, moisture, and light, even after the final product was prepared.
- ambroxol hydrochloride impurity B trans-4-(6,8-dibromo-1 ,4- dihydroquinazolin-3(2H)-yl)cyclohexanol.
- This is a well-known compound, reported on European Pharmacopoeia as possible impurity of the active ingredient, due to the interaction between ambroxol with formaldehyde.
- Other possible impurities due to oxidation reactions are impurity A [(2-amino-3,5-dibromophenyl) methanol] and impurity E (2amino3,5dibromo benzaldeyde).
- WO 2015/177147 presents a cough syrup containing ambroxol hydrochloride with giving a solution to stability problem of ambroxol hydrochloride in liquid form.
- This problem is solved formulating a cough syrup containing ambroxol hydrochloride with substantially free from glycerol and sugar alcohol.
- the product contains less than 1 g and particularly preferably less than 0.5 g glycerol and similarly less than 5 g and particularly preferably less than 1 g sugar alcohol based in each case on 100 ml_ of the cough syrup.
- ambroxol hydrochloride impurity B originated by degradation of the active ingredient is a common problem of drug products and in particular of liquid forms. Of course, it must be regarded as a negative aspect which may limit the stability of the product. However, under certain storage conditions involving contact with the air, stability problems can still occur. Therefore, there still exists a need for new stable syrup formulations.
- a stable, liquid formulation comprising terbutaline sulphate and ambroxol hydrochloride is studied.
- This combination has the same efficacy with each pharmaceutical composition separately even in a small quantity, e.g., 10 mL or less, for improving patient compliance.
- the present invention relates to a unit-dose combination formulation for the combined delivery of terbutaline sulphate and ambroxol hydrochloride.
- a chemically and physically stable dosage form which can provide therapeutic levels of terbutaline sulphate and ambroxol hydrochloride from the same unit-dose formulation in a fashion similar to each of the separate products available commercially would be extremely beneficial in the treatment of bronchial asthma for patients.
- the combination of terbutaline sulphate and ambroxol hydrochloride product is not available in the market. Hence there is a need for patient compliant combination of terbutaline sulphate and ambroxol hydrochloride for treatment of bronchial asthma in order to eliminate taking each drug three times a day.
- compositions of the invention are prepared by formulating the active agents together with at least one pharmaceutically acceptable excipient and combining them in a single dosage form.
- the aim of the present invention was to develop, formulate and evaluation of terbutaline sulphate and ambroxol hydrochloride syrup formulation for maintenance treatment of lung diseases that have emerged as a secretion complication of asthma and bronchospasm.
- Another aim of the present invention was to provide an oral pharmaceutical syrup composition comprising terbutaline sulphate and ambroxol hydrochloride wherein a significantly improved pharmaceutical stability.
- an oral pharmaceutical syrup composition wherein the pH of the composition is optimized within a range for solubility of the active ingredients.
- a sugar-free oral pharmaceutical syrup composition with a pleasant taste.
- pharmaceutical composition of the present invention has a pleasant taste that permits it to be administrated to children without any reluctance.
- terbutaline and “ambroxol” used in the present invention refers to free bases or pharmaceutically acceptable salts, enantiomers, racemates, solvates, hydrates, various polymorphic forms, amorphous and crystalline forms of said active agents or combinations thereof.
- terbutaline sulphate and ambroxol hydrochloride were used.
- terbutaline sulphate and ambroxol hydrochloride are considered to cooperate favorable in the treatment of bronchial asthma.
- Terbutaline sulphate is a B2-adrenergic receptor agonist used to provide relaxation of bronchial smooth muscles;
- ambroxol hydrochloride is a mucolytic agent used to treat respiratory diseases associated with viscid or excessive mucus accumulated in respiratory track. Therefore this product is used for maintenance treatment of lung diseases that have emerged as a secretion complication of asthma and bronchospasm.
- An even further object of the present invention is to obtain a combination formulation wherein the product may provide a better advantage to the patients by improving therapeutic activity compared to monotherapy.
- compositions of this invention are used as liquid preparations of oral administration as syrup.
- thickening agent of the present invention is selected from the group comprising, but not limited to, cellulose derivatives which can be cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, methyl cellulose, microcrystalline cellulose and the like or combination thereof.
- cellulose derivatives which can be cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, methyl cellulose, microcrystalline cellulose and the like or combination thereof.
- HEC hydroxyethyl cellulose
- preservatives like alcohols, benzoates, sorbates, and parabens is common in liquid formulations. Preservatives are effective in controlling mold, inhibiting yeast growth and protecting against bacterial proliferation, thus, finally, to allow compliance with the European Pharmacopoeia microbiological specifications (Ph. Eur. 6.7, 5.1 .4) for "aqueous preparations for oral use” or "aqueous preparations for oromucosal use”. The use of preservatives is particularly recommended in aqueous compositions, wherein microorganisms can find favorable conditions for their propagation.
- the solution of this invention preferably comprises a taste masking agent.
- acesulfam potassium was used both as sweetener and bitter taste masking agent.
- the oral pharmaceutical syrup composition has a pH range of between 2.5-4.5 values with using a pH adjustment agent namely citric acid monohydrate.
- the oral liquid pharmaceutical composition can also contain other excipients commonly found in pharmaceutical compositions such as diluent and flavoring agent.
- compositions of this invention are detailed below showing examples. However, pharmaceutical compounds of this invention are not restricted to the following examples.
- Total of 150 ml syrup was manufactured by dissolving the following ingredients in distilled water.
- Citric Acid Monohydrate q.s.
- Terbutaline sulphate and ambroxol hydrochloride which are active in the formulation, completely dissolve in water to form a clear solution. Additions should be made taking into account the water solubility and properties of the active substances and auxiliary substances.
- HEC hydroxyethyl cellulose
- the pH of the syrup was adjusted to 2.1 with using required amount of citric acid monohydrate. All ingredients were dissolved in adequate amount of deionized water to prepare 150 mL total syrup.
- Example 2 hydroxyethyl cellulose
- Total of 150 ml syrup was manufactured by dissolving the following ingredients in distilled water.
- Terbutaline sulphate and ambroxol hydrochloride which are active in the formulation, completely dissolve in water to form a clear solution. Additions should be made taking into account the water solubility and properties of the active substances and auxiliary substances.
- HEC hydroxyethyl cellulose
- all excipients were mixed without using citric acid monohydrate as pH adjustment agent. Therefore final pH of syrup was 5.00 without any adjustment.
- Total of 150 ml syrup was manufactured by dissolving the following ingredients in distilled water.
- Citric Acid Monohydrate q.s.
- Terbutaline sulphate and ambroxol hydrochloride which are active in the formulation, completely dissolve in water to form a clear solution. Additions should be made taking into account the water solubility and properties of the active substances and auxiliary substances.
- HEC hydroxyethyl cellulose
- the pH of the syrup was adjusted to between 2.5-4.5 with using required amount of citric acid monohydrate. All ingredients were dissolved in adequate amount of deionized water to prepare 150 mL total syrup.
- Total of 150 ml syrup was manufactured by dissolving the following ingredients in distilled water.
- Citric Acid Monohydrate q.s.
- Terbutaline sulphate and ambroxol hydrochloride which are active in the formulation, completely dissolve in water to form a clear solution. Additions should be made taking into account the water solubility and properties of the active substances and auxiliary substances.
- HEC hydroxyethyl cellulose
- the pH of the syrup was adjusted to between 2.5-4.5 with using required amount of citric acid monohydrate. All ingredients were dissolved in adequate amount of deionized water to prepare 150 mL total syrup.
- Example 1 Example 2 Example 3 Example 4
- ambroxol impurity B should not exceed 0.2% (w/w) limit.
- the amount of impurity B was lower than ICH impurity limit when compared with example 1 -2 and 4 at initial conditions.
- HEC hydroxyethyl cellulose
- pH of the syrup are critical parameters for the impurity profile. Both the change in the hydroxyethyl cellulose (HEC) amount and the change in the pH value cause an increase in the amount of ambroxol impurity B. Therefore in this invention these two parameters were fixed in order to have stable syrup formulation.
- the stability of a drug substance is an important factor in the manufacture of safe and effective pharmaceutical products. Stability studies are required to be submitted by any applicant seeking approval for a new pharmaceutical product.
- the rules in force e.g. "Note for Guidance on Impurities in New Drug Products” CPMP/ICH/2738/99, issued by EMEA, European Medicines Agency) provide strict limitations for impurities, nevertheless it is better to prevent or reduce as possible the degradation to avoid the exposure of patients to substances.
- Accelerated stability tests are performed by storing a product in stress conditions. These tests allow predicting the shelf life of the product over the years when it will be stored in normal storage conditions.
- the accelerated stability test in this case was performed according to the EMEA Guideline on Stability Testing (CPMP/QWP/122/02, rev 1 ), i.e. by maintaining the product in its container at a temperature of 40 °C ⁇ 2°C and 75% ⁇ 5 %RH (Relative Humidity) for six months.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/TR2017/050118 WO2018182546A1 (fr) | 2017-03-27 | 2017-03-27 | Composition de sirop pharmaceutique stabilisée comprenant du sulfate de terbutaline et du chlorhydrate d'ambroxol |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3600275A1 true EP3600275A1 (fr) | 2020-02-05 |
Family
ID=58668942
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17721224.8A Withdrawn EP3600275A1 (fr) | 2017-03-27 | 2017-03-27 | Composition de sirop pharmaceutique stabilisée comprenant du sulfate de terbutaline et du chlorhydrate d'ambroxol |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP3600275A1 (fr) |
WO (1) | WO2018182546A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113633607A (zh) * | 2021-08-17 | 2021-11-12 | 北京四环科宝制药有限公司 | 含有盐酸氨溴索的药物组合物及其制备方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE335359B (fr) | 1966-10-19 | 1971-05-24 | Draco Ab | |
US20030171391A1 (en) | 2002-01-25 | 2003-09-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ambroxol for the treatment of chronic pain |
EP1417961A1 (fr) | 2002-11-08 | 2004-05-12 | Boehringer Ingelheim International GmbH | Nouvelle composition pharmaceutique comprenant une combinaison d'ambroxol ou de bromhexine et d'iodure d'isopropamide |
ITMI20032463A1 (it) | 2003-12-16 | 2005-06-17 | Advance Holdings Ltd | Soluzione acquosa concentrata a base di ambroxolo |
CN102309442A (zh) * | 2010-07-07 | 2012-01-11 | 澳美制药厂 | 盐酸氨溴索口服水性组合物及其制备方法 |
WO2013081565A1 (fr) | 2011-11-21 | 2013-06-06 | Mahmut Bilgic | Compositions pharmaceutiques comportant du roflumilast et de la terbutaline |
KR101915056B1 (ko) | 2012-04-10 | 2018-11-07 | 한미약품 주식회사 | 암브록솔, 레보드로프로피진 및 완충제를 포함하는 경구용 액상 제제 및 이의 제조방법 |
MX2016015303A (es) | 2014-05-23 | 2017-03-06 | Boehringer Ingelheim Int | Jarabe para la tos que contiene clorhidrato de ambroxol. |
CN105287367B (zh) | 2015-10-13 | 2018-07-10 | 华润三九(南昌)药业有限公司 | 一种盐酸氨溴索的口服液体制剂及其制备方法与应用 |
-
2017
- 2017-03-27 EP EP17721224.8A patent/EP3600275A1/fr not_active Withdrawn
- 2017-03-27 WO PCT/TR2017/050118 patent/WO2018182546A1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
WO2018182546A1 (fr) | 2018-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5683719B2 (ja) | ベポタスチン組成物 | |
JP4950063B2 (ja) | 薬学的製剤 | |
NO334441B1 (no) | Preparat for behandling av vanlig forkjølelse. | |
EP2624836B1 (fr) | Compositions de bépotastine | |
BRPI0713933A2 (pt) | xaropes anti-histamìnicos estáveis a armazenamento sem açúcar | |
US9119777B2 (en) | Methods and compositions for administration of oxybutynin | |
TWI589305B (zh) | 用於經口投藥之包含安布索、左旋羥丙哌嗪及緩衝劑的液體調配物以及製備其之方法 | |
AU2005212355B2 (en) | Controlled release formulations | |
US8748488B2 (en) | Methods and compositions for administration of oxybutynin | |
EP3600275A1 (fr) | Composition de sirop pharmaceutique stabilisée comprenant du sulfate de terbutaline et du chlorhydrate d'ambroxol | |
KR102083621B1 (ko) | 암브록솔 및 레보드로프로피진을 포함하는 안정성이 개선된 경구용 액상 제제 | |
US20080207667A1 (en) | Use of nalbuphine and related compounds to treat symptoms of respiratory problems | |
CN113712920B (zh) | 一种盐酸氨溴索口腔喷雾剂及制备方法 | |
TR2022010733A1 (tr) | Terbutali̇n ve guai̇fenesi̇n i̇çeren stabi̇l oral li̇ki̇t bi̇leşi̇m | |
CN116763726A (zh) | 一种盐酸西替利嗪口服溶液及其制备方法 | |
CN112716945A (zh) | 药物组合物及其应用 | |
WO2002019995A2 (fr) | Utilisation d'une combinaison pharmaceutique | |
AU2002329578A1 (en) | Compositions for treatment of common cold |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20191015 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20210520 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20230803 |